Can bone healing in distraction osteogenesis be accelerated by local application of IGF-1 and TGF-beta1?
Because complications of distraction osteogenesis are largely related to the long duration of therapy, increasing efforts were reached to shorten treatment by using osteoconductive replacement materials incorporating bioactive molecules such as IGF-1 and TGF-beta1. The controlled release of IGF-1 and TGF-beta1 from coated biodegradable poly(D,L-lactide) implants could stimulate fracture healing locally. We investigated the effect of locally applied IGF-1 and TGF-beta1 from IGF-1/TGF-beta1-enriched polylactide membranes on fracture healing in a sheep model of delayed callus formation. Twenty-eight sheep were used for this study. Callus distraction of 1 mm/day by means of a unilateral fixator was continued for 30 days. At the beginning of the subsequent consolidation phase, either growth factors were applied locally or the defect was packed with cancellous bone, or both. The groups treated with growth factors were compared to a control group. The consolidation phase lasted for 60 days and both tibiae were dissected for histological and histomorphometric analyses. This investigation found a reduced absolute callus area in the lengthening zone in all treatment groups. The two treatment groups that received a membrane coated with growth factors showed distinctly higher relative bone areas than the groups treated with an uncoated membrane or packing of the osteotomy defect with cancellous bone. The differences in bone areas were not statistically significant. Application of the growth factors accelerated bone healing and achieved results comparable with those of established treatment methods (packing with autologous cancellous bone). The best results were achieved with a combination of both methods.
Bernstein
Anke
A
Department of Orthopedics, Martin Luther University of Halle-Wittenberg, Halle 06097, Germany. anke.bernstein@medizin.uni-halle.de
Mayr
Hermann O
HO
Hube
Robert
R
D000818:Animals; D017102:Fracture Healing; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage*; D019857:Osteogenesis, Distraction; D012756:Sheep; D053773:Transforming Growth Factor beta1 / Q000008:administration & dosage*
D053773:Transforming Growth Factor beta1; D007334:Insulin-Like Growth Factor I